About Uroplasty (NASDAQ:UPI)
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Industry, Sector and Symbol
Industry Medical Devices & Implants
Trailing P/E Ratio-4.06666666666667
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-87.33%
Return on Assets-60.82%
Uroplasty (NASDAQ:UPI) Frequently Asked Questions
What is Uroplasty's stock symbol?
Uroplasty trades on the NASDAQ under the ticker symbol "UPI."
How were Uroplasty's earnings last quarter?
Uroplasty, Inc. (NASDAQ:UPI) issued its quarterly earnings results on Thursday, January, 22nd. The medical device company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.02. The medical device company earned $6.67 million during the quarter, compared to analysts' expectations of $6.89 million. Uroplasty had a negative return on equity of 87.33% and a negative net margin of 31.58%. View Uroplasty's Earnings History.
Who are some of Uroplasty's key competitors?
Some companies that are related to Uroplasty include Amryt Pharma (AMYT), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), Scancell (SCLP), Ocera Therapeutics (OCRX), VolitionRX (VNRX), Electromed (ELMD), Biopharmx (BPMX), Scientific Digital Imaging (SDI), Futura Medical (FUM), Advanced Oncotherapy (AVO), ANGLE (AGL), Concordia International (CXR), Actinium Pharmaceuticals (ATNM), Can Fite Biopharma (CANF), Surgical Innovations (SUN) and ReNeuron Group (RENE).
Has Uroplasty been receiving favorable news coverage?
Headlines about UPI stock have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Uroplasty earned a coverage optimism score of 0.19 on Accern's scale. They also assigned press coverage about the medical device company an impact score of 46.87 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Uroplasty?
Shares of UPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uroplasty's stock price today?
One share of UPI stock can currently be purchased for approximately $1.22.
How big of a company is Uroplasty?
Uroplasty has a market capitalization of $27.68 million.
How can I contact Uroplasty?
Uroplasty's mailing address is 5420 Feltl Road, MINNETONKA, MN 55343, United States. The medical device company can be reached via phone at +1-952-4266140.
MarketBeat Community Rating for Uroplasty (UPI)MarketBeat's community ratings are surveys of what our community members think about Uroplasty and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Uroplasty (NASDAQ:UPI) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Uroplasty (NASDAQ:UPI) Earnings History and Estimates Chart
Uroplasty (NASDAQ UPI) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/22/2015||Q3||($0.04)||($0.06)||$6.89 million||$6.67 million||View||Listen|
|10/23/2014||Q2||($0.07)||($0.05)||$6.49 million||$6.46 million||View||Listen|
|7/24/2014||Q1||($0.05)||($0.10)||$6.35 million||$6.39 million||View||Listen|
|5/15/2014||Q4 13||($0.04)||($0.05)||$6.40 million||$6.36 million||View||N/A|
|1/23/2014||Q314||($0.04)||($0.03)||$6.13 million||$6.40 million||View||Listen|
|10/24/2013||Q214||($0.05)||($0.04)||$6.09 million||$6.00 million||View||Listen|
|8/1/2013||Q1 2014||($0.05)||($0.08)||$5.60 million||$5.84 million||View||N/A|
|5/30/2013||Q4 2013||($0.04)||($0.05)||$5.59 million||$5.54 million||View||Listen|
Uroplasty (NASDAQ:UPI) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Uroplasty (NASDAQ:UPI)
No dividend announcements for this company have been tracked by MarketBeat.com
Uroplasty (NASDAQ UPI) Insider Trading and Institutional Ownership History
Uroplasty (NASDAQ UPI) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/30/2015||Brett Reynolds||CFO||Buy||5,000||$1.32||$6,600.00|| |
|1/29/2015||Kevin H Roche||Director||Buy||50,000||$1.23||$61,500.00|| |
|1/29/2015||Robert Kill||CEO||Buy||25,000||$1.26||$31,500.00|| |
|7/30/2014||Kevin H Roche||Director||Buy||10,000||$2.45||$24,500.00|| |
|7/29/2014||Kevin H Roche||Director||Buy||9,000||$2.44||$21,960.00|| |
|6/3/2014||Kevin H Roche||Director||Buy||10,000||$2.97||$29,700.00|| |
|6/2/2014||Robert Kill||CEO||Buy||13,950||$2.95||$41,152.50|| |
|3/6/2014||Susan Hartjes Holman||VP||Sell||38,000||$3.98||$151,240.00||274,680|| |
|1/29/2014||Susan Hartjes Holman||SVP||Sell||52,500||$4.59||$240,975.00||312,680|| |
|12/11/2013||Robert Patrick Maxwell||Director||Sell||3,819||$2.70||$10,311.30||136,584|| |
|8/23/2013||Brett Reynolds||CFO||Buy||8,000||$2.99||$23,920.00||58,000|| |
|8/23/2013||James Stauner||Director||Buy||8,300||$3.03||$25,149.00||35,450|| |
|8/7/2013||Robert Kill||CEO||Buy||36,050||$2.77||$99,858.50||346,050|| |
|8/6/2013||Darin Hammers||VP||Buy||6,800||$2.82||$19,176.00||6,800|| |
Uroplasty (NASDAQ UPI) News Headlines
Uroplasty (NASDAQ:UPI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Uroplasty (NASDAQ:UPI) Income Statement, Balance Sheet and Cash Flow Statement
Uroplasty (NASDAQ UPI) Stock Chart for Wednesday, March, 21, 2018